Osteoporosis

>

Latest News

FDA Approves Celltrion’s Denosumab Biosimilars for Bone Loss Indications
FDA Approves Celltrion’s Denosumab Biosimilars for Bone Loss Indications

March 4th 2025

The biosimilars are expected to become available in the US in June 2025.

Carolyn J. Crandall, MD, MS, UCLA
USPSTF Finalizes 2024 Osteoporosis Screening Recommendations

January 14th 2025

Jean-Yves Reginster, MD, PhD, Outstanding Professor of Epidemiology, Public Health and Health Economics, and Professor of Bioethics and Societal Medicine, and Honorary Chair of the Bone and Cartilage Metabolism Unit, at the University of Liège
Denosumab Biosimilar Demonstrates Equivalent Efficacy, Safety in Phase 3 Trial

December 3rd 2024

New Report Reveals 1 Fracture Occurs Every Minute in France’s Population
New Report Reveals 1 Fracture Occurs Every Minute in France’s Population

September 10th 2024

More News

© 2025 MJH Life Sciences

All rights reserved.